Cheetham Group

Two AIBN researchers have received Tour de Cure funding to develop mRNA-based immunotherapies

UQ has been named as a key research node for CoRE-MitoGT - the Medical Research Council Centre of Research Excellence for Mitochondrial Genome Therapeutics

Talking to Seth Cheetham, a leading researcher in targeted therapeutics and biomanufacturing, and the new director of the National Biologics Facility

What do 4D printed robots, fish food, flow batteries, PFAS remediation, next-gen mRNA, and indoor solar panels have in common?

Queensland is cementing its global leadership in mRNA science with the launch of a new protocol designed to make its research more accessible than ever before.

With the support of the Lily Foundation, University of Cambridge Neurologist Dr Jelle van den Ameele and AIBN group leader Dr Seth Cheetham are hoping to change the fortunes of those born with a fatal condition.

Nissa Carrodus has trained countless students in the ways of the lab over her 15 years as a research assistant. Now she’s starting a PhD of her own.

A new facility at the Australian Institute for Bioengineering and Nanotechnology is set to provide researchers with cancer vaccines tailored to individual patients.

A new parcel of federal funding will help AIBN researchers produce clinical-grade mRNA products that are safer and better quality, and will potentially cost less.

As we close the book on 2022 it is time to look at how far the AIBN has come during the year, and how we are setting ourselves up for an even bigger 2023.